I learned today that a Chinese pharmaceutical company has given up on installing Innovation and Development Center of the Commune of Antofagasta. In a statement, the company explained its reasons for abandoning the project and clarified that it remains in the country and is currently conducting a range of commercial and research activities.
“As we all know, in July 2021, Sinovac Chile, in cooperation with the government and regional authorities, Visit the city of Antofagastawith the aim of understanding the land available for future scientific research and development centres,” the company said.
He added, “After detailed review and study of the proposal, May 2022 The company publicly stated that a technical analysis of the land provided did not meet the characteristics of a research center. ” This is due to, among other reasons, access to potable water.
The Chinese company said it was working with the University of Antofagasta ” Sign future agreements R&D collaboration, which demonstrates Sinovac’s willingness to continue working in the region. “
On the other hand, he stated that they will continue to operate in Chile and that they are Undertake a series of projects.
“From a business perspective, Sinovac Chile currently has health register marketing Flu vaccine, three additional health records are currently being processed by the Institute of Public Health (ISP), including those for hepatitis A and chickenpox vaccines. “This shows Sinovac’s willingness to join Chile’s private and public vaccine markets,” he noted.
Likewise, he noted that “Sinovac Chile is currently developing a series of research projects Cooperation with different institutions such as the Pontifical Catholic University of Chile, Milenio Institute and Universidad del Desarrollo. Needless to say, our business offices are located in the Innovation Center of the Catholic University of San Joaquin campus. “
About construction projects Kilikula vaccine filling plant“Sinovac does not rule out the possibility of building a vaccine filling plant, but has determined that the first step is to join the Chilean market through import and marketing,” the company said.
Finally about Colombia Projectthe company made it clear that it is completely independent from Sinovac’s initiatives in my country.
“Sinovac announced in April 2023 that it had signed an agreement with the Colombian government and the city of Bogota to jointly develop a vaccine production plant in the Colombian capital. Sinovac explained that the project was the result of a public tender issued by the Bogota government in 2022 to build the above-mentioned factory. As part of this, multiple vaccine manufacturing companies around the world are involved.
He then added, “We are interested in pointing out that the Bogota project is completely independent of Sinovac’s projects in Chile, it is part of Sinovac’s regional projects in Latin America and it will not hinder or affect Sinovac’s permanent projects in Chile. “Our country’s company”.